Scholar Rock Holding, a biotech targeting growth factor inhibition for spinal muscular atrophy, raised $75 million by offering 5.36 million shares at $14, within the range of $13 to $15. At that price, it commands a fully-diluted market value of $350 million.
Scholar Rock plans to list on the Nasdaq under the symbol SRRK. Jefferies, Cowen & Company and BMO Capital Markets acted as lead managers on the deal.
